Clinical Trials Logo

Benign Prostatic Hypertrophy clinical trials

View clinical trials related to Benign Prostatic Hypertrophy.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03630926 Active, not recruiting - Prostate Cancer Clinical Trials

Evaluation of the NV-VPAC1 Prostate Cancer (PCa) Urine Diagnostic Test in Subjects With Biopsy-confirmed Prostate Cancer, Benign Prostatic Hypertrophy, or Bladder/Kidney Stones.

VPAC
Start date: October 16, 2018
Phase:
Study type: Observational

This is a double-blind, study to evaluate the performance of NV-VPAC1 PCa Urine Diagnostic Test in three distinct populations being treated at the Intermountain Urology Clinic. The first population (positive control) is comprised of men with biopsy-confirmed PCa who are scheduled for prostatectomy. The second population (negative control) is comprised of men with benign prostatic hypertrophy (BPH) who are scheduled for transurethral resection of the prostate (TURP). The third population (negative control) is comprised of men or women with bladder/kidney stones who are scheduled for a cystoscopy.

NCT ID: NCT03423979 Active, not recruiting - Clinical trials for Benign Prostatic Hyperplasia

Optilumeā„¢ BPH Prostatic Drug Coated Balloon Dilation Catheter

EVEREST-I
Start date: December 19, 2017
Phase: Phase 2
Study type: Interventional

A prospective, non-randomized study. The subjects will be enrolled and treated with the Optilume BPH Prostatic DCB Dilation Catheter System at up to 8 clinical sites. The post-treatment follow-up visit can be up to 5 years. The objective of the study is to evaluate the safety and efficacy of the Optilumeā„¢ BPH Prostatic Drug Coated Balloon Dilation Catheter System in the treatment of BPH.